Literature DB >> 20811297

Orthopedic complications related to growth hormone therapy in a pediatric population.

Rachid K Haidar1, Mona P Nasrallah, Asdghig H Der-Boghossian, Ismat B Ghanem.   

Abstract

Since the introduction of recombinant growth hormone, its use has diversified and multiplied. Growth hormone is now the recommended therapy for a growing indication to all forms of short stature because of its direct and indirect role on bone growth. Hereby, we discuss the orthopedic complications associated with growth hormone treatment in pediatric patients. These complications include carpal tunnel syndrome, Legg-Calve-Perthes' disease, scoliosis, and slipped capital femoral epiphysis. Their incidence rates recorded in several growth hormone therapy-related pharmacovigilance studies will be summarized in this study with focused discussion on their occurrence in the pediatric and adolescent age groups. The pathogenesis of these complications is also reviewed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20811297     DOI: 10.1097/BPB.0b013e32833ed967

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  3 in total

1.  Legg-Calve-Perthes disease in an 8-year old girl with Acrodysostosis type 1 on growth hormone therapy: case report.

Authors:  Whei Ying Lim; Emily L Germain-Lee; Nancy S Dunbar
Journal:  Int J Pediatr Endocrinol       Date:  2020-08-07

2.  Childhood cancer survivors exposed to total body irradiation are at significant risk for slipped capital femoral epiphysis during recombinant growth hormone therapy.

Authors:  Sogol Mostoufi-Moab; Elizabeth J Isaacoff; David Spiegel; Denise Gruccio; Jill P Ginsberg; Wendy Hobbie; Justine Shults; Mary B Leonard
Journal:  Pediatr Blood Cancer       Date:  2013-07-02       Impact factor: 3.167

3.  A Case of Growth Hormone Use in Dyggve-Melchior-Clausen Syndrome.

Authors:  Ravi Upadhyay; Claire Ruane; Rachel Umans; Beth A Pletcher; Aditi Khokhar; Kristin Wong
Journal:  Case Rep Endocrinol       Date:  2022-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.